

Hai Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11844562/publications.pdf>

Version: 2024-02-01

17
papers

5,378
citations

471509

17
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

7635
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptional co-activator PGC-1 β drives the formation of slow-twitch muscle fibres. <i>Nature</i> , 2002, 418, 797-801.	27.8	2,232
2	NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. <i>Nature</i> , 2006, 441, 595-600.	27.8	639
3	Regulation of Mitochondrial Biogenesis in Skeletal Muscle by CaMK. <i>Science</i> , 2002, 296, 349-352.	12.6	583
4	A Protein Encoded within the Down Syndrome Critical Region Is Enriched in Striated Muscles and Inhibits Calcineurin Signaling. <i>Journal of Biological Chemistry</i> , 2000, 275, 8719-8725.	3.4	380
5	Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. <i>Journal of Clinical Investigation</i> , 2007, 117, 2459-2467.	8.2	360
6	Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. <i>Nature Medicine</i> , 2002, 8, 1303-1309.	30.7	282
7	Calcineurin/NFAT Signaling Is Required for Neuregulin-Regulated Schwann Cell Differentiation. <i>Science</i> , 2009, 323, 651-654.	12.6	190
8	NFAT signaling and the invention of vertebrates. <i>Trends in Cell Biology</i> , 2007, 17, 251-260.	7.9	182
9	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G ₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2987-2999.	1.6	126
10	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 7.	17.0	113
11	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4250-4259.	7.0	104
12	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	2.8	46
13	Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 710-718.	6.1	38
14	Down Syndrome Critical Region-1 Is a Transcriptional Target of Nuclear Factor of Activated T Cells-c1 within the Endocardium during Heart Development. <i>Journal of Biological Chemistry</i> , 2007, 282, 30673-30679.	3.4	30
15	Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. <i>MAbs</i> , 2019, 11, 681-690.	5.2	30
16	Transcriptional analysis of mouse skeletal myofiber diversity and adaptation to endurance exercise. <i>Journal of Muscle Research and Cell Motility</i> , 2003, 24, 587-592.	2.0	24
17	Activation of the MEF2 transcription factor in skeletal muscles from myotonic mice. <i>Journal of Clinical Investigation</i> , 2002, 109, 1327-1333.	8.2	19